Condition

Hormone-receptor-positive Breast Cancer clinical trials and research

• 29Clinical trials
• 1New in 30 days
• 16Countries

Newest Hormone-receptor-positive Breast Cancer clinical trials

All recruiting trials (29)

• PRT13722 in advanced HR+/HER2- breast cancer

  This early study tests PRT13722, by itself and with standard therapies, to see if it is safe and has any signs of activity in adults with HR+/HER2- breast cancer who have progressed on prior treatments.

  Recruiting Phase 1 Prelude Therapeutics Incorporated · Maumee, Ohio · NCT07905001

• Breast cancer subtypes and outcomes in Colombian women

  This study looks back at medical records of women with breast cancer to see how different molecular subtypes relate to survival and recurrence in a single Colombian hospital.

  Recruiting Fundación Santa Fe de Bogota · Bogotá, Bogota D.C. · NCT07856225

• Culmerciclib with endocrine therapy before surgery for early HER2-negative hormone receptor-positive breast cancer

  This trial tests whether adding culmerciclib to an aromatase inhibitor before surgery helps women with certain early breast cancers better shrink tumors than an aromatase inhibitor alone.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07796880

• Entinostat with Pyrotinib and Endocrine Therapy in HER2-positive, HR-positive Advanced Breast Cancer after Trastuzumab Failure

  This study tests whether adding entinostat to pyrotinib and hormone therapy is safe and helps patients with advanced HR+/HER2+ breast cancer who progressed after trastuzumab.

  Recruiting Phase 1/2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07708194

• Everolimus After Alpelisib in HR+ Metastatic Breast Cancer

  This study tests whether adding everolimus to endocrine therapy can help HR+ metastatic breast cancer patients who progressed on a PI3K inhibitor see a benefit.

  Recruiting Tel-Aviv Sourasky Medical Center · Tel Aviv · NCT07646171

• CDK4/6 inhibitors with endocrine therapy before surgery for HR+/HER2- high-risk early breast cancer

  This study tests whether adding a CDK4/6 inhibitor to endocrine therapy before surgery can help guide safer de-escalation of chemotherapy using ctDNA as a marker.

  Recruiting Phase 2 Peking University People's Hospital · Beijing, Beijing Municipality · NCT07366112

• Gut microbiome differences in people on abemaciclib who do or don't get diarrhea

  This project will compare gut bacteria in people with HR-positive breast cancer who are taking abemaciclib to see if differences are linked to developing diarrhea.

  Recruiting Hubei Cancer Hospital · Wuhan, Hubei · NCT07264998

• Capecitabine with or without elacestrant for ER-positive advanced breast cancer

  This trial will try adding elacestrant to capecitabine to see if it helps people with ER-positive, HER2-negative advanced breast cancer that stopped responding to CDK4/6 inhibitors.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07222215

• Treatment options after targeted therapy stops working in advanced breast cancer

  This study will see how well different treatments work for people with advanced breast cancer who have stopped responding to CDK4/6 inhibitors, PIK3CA inhibitors, or T-DXd.

  Recruiting Hunan Cancer Hospital · Changsha, Hunan · NCT07073755

• Revaree Plus for vaginal dryness in people with breast cancer

  This trial will test whether Revaree Plus can improve vaginal dryness and related discomfort in adults with hormone-receptor–positive stage 0–III breast cancer who are on tamoxifen, aromatase inhibitors, or SERMs.

  Recruiting at 7 sites Phase 4 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07042581

• ctDNA-guided reduction of chemotherapy using dalpiciclib plus endocrine therapy in high-risk HR+/HER2- early breast cancer

  This trial tests whether giving the CDK4/6 drug dalpiciclib with endocrine therapy and using ctDNA results can let some women with early high-risk HR+/HER2- breast cancer skip or reduce chemotherapy.

  Recruiting Phase 2 Peking University People's Hospital · Beijing, Beijing Municipality · NCT06970912

• Predicting outcomes for advanced breast cancer patients treated with CDK4/6 inhibitors and endocrine therapy

  This study is trying to see how well different CDK4/6 inhibitors combined with hormone therapy work for people with advanced breast cancer and how safe they are.

  Recruiting at 24 sites Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Aviano and 23 other locations · NCT06805812

• Predicting outcomes for advanced breast cancer patients treated with CDK4/6 inhibitors and endocrine therapy

  This study is trying to see how well different CDK4/6 inhibitors combined with hormone therapy work for people with advanced breast cancer and how safe they are.

  Recruiting at 24 sites Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Aviano and 23 other locations · NCT06805812

• Testing a new combination of drugs for advanced breast cancer

  This study is testing a new combination of drugs to see if they can help adults with advanced breast cancer that hasn't responded to previous treatments.

  Recruiting at 13 sites Phase 1 BeOne Medicines · Iowa City, Iowa and 13 other locations · NCT06756932

• Testing Abemaciclib with Radiation Therapy for Metastatic Breast Cancer

  This study is testing different doses of the drug abemaciclib in people with metastatic breast cancer who are also getting hormone therapy and radiation to see if it helps them better manage their symptoms.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06678269

• Evaluating XB010 for patients with solid tumors

  This study is testing a new drug called XB010, alone and with another medication, to see if it can help people with advanced solid tumors who have few other treatment options.

  Recruiting at 18 sites Phase 1 Exelixis · Irvine, California and 19 other locations · NCT06545331

• Using tirzepatide to help with weight loss in early-stage breast cancer patients

  This study is testing if the medication tirzepatide can help women with early-stage breast cancer lose at least 5% of their body weight while they receive treatment.

  Recruiting at 6 sites Phase 2 Rutgers, The State University of New Jersey · Elizabeth, New Jersey and 6 other locations · NCT06518837

• Measuring a biomarker for breast cancer treatment effectiveness

  This study is testing if measuring a specific biomarker can help doctors understand how well hormone treatments are working for people with advanced breast cancer.

  Recruiting Mayo Clinic · Jacksonville, Florida · NCT06388122

• Evaluating the effectiveness of sacituzumab govitecan in specific breast cancer patients

  This study is testing if a drug called sacituzumab govitecan can help people with advanced hormone receptor-positive breast cancer who have already been treated with another medication.

  Recruiting at 3 sites Phase 2 Baptist Health South Florida · Miami, Florida and 2 other locations · NCT06263543

• ARX788 for HER2-low breast cancer

  This phase 2 study tests ARX788 as a single-drug treatment for adults with HER2-low locally advanced unresectable or metastatic breast cancer.

  Recruiting Phase 2 University of California, San Francisco · San Francisco, California · NCT06224673

• BGB-43395 treatment for advanced breast cancer and other solid tumors

  This study is testing a new treatment called BGB-43395 for people with advanced breast cancer and other solid tumors to see if it works better alone or with other medications.

  Recruiting at 57 sites Phase 1 BeOne Medicines · Denver, Colorado and 60 other locations · NCT06120283

• Platform program for evaluating treatments in metastatic HER2-positive breast cancer

  This study is testing different new treatments for people with advanced HER2-positive breast cancer to see which ones work best before moving them to larger trials.

  Recruiting at 5 sites Phase 1/2 QuantumLeap Healthcare Collaborative · Birmingham, Alabama and 9 other locations · NCT05868226

• Combining VS-6766, Abemaciclib, and Fulvestrant for HR+/HER2-negative Breast Cancer

  This study is testing if a new drug called VS-6766, when combined with two other medications, can help people with hormone receptor-positive and HER2-negative metastatic breast cancer feel better.

  Recruiting at 2 sites Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT05608252

• Evaluating Vosilasarm for Advanced Breast Cancer Treatment

  This study is testing a new drug called Vosilasarm to see how well it works on its own and with other treatments for people with advanced breast cancer.

  Recruiting at 13 sites Phase 1/2 Ellipses Pharma · New Haven, Connecticut and 13 other locations · NCT05573126

• Combination therapy for hormone receptor-positive metastatic breast cancer

  This study is testing a new combination of three medications to see if it can help people who have just been diagnosed with advanced hormone receptor-positive breast cancer or those who have had a relapse after being cancer-free for over a year.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT05524584

• Treatment for male breast cancer using endocrine therapy

  This study is testing different combinations of hormone therapy for men with early to mid-stage breast cancer to see which one works best compared to the usual treatment.

  Recruiting at 9 sites Phase 2 Dana-Farber Cancer Institute · Washington D.C., District of Columbia and 8 other locations · NCT05501704

• Ribociclib and hormone therapy for recurrent breast cancer

  This study is testing if a new drug called ribociclib, when combined with hormone therapy, can help people with recurrent hormone receptor-positive breast cancer feel better and manage their condition.

  Recruiting at 19 sites Phase 2 Hoosier Cancer Research Network · Birmingham, Alabama and 20 other locations · NCT05467891

• Screening brain MRIs for patients with stage IV breast cancer

  This study tests if regular brain MRI scans can help find hidden issues in the brains of patients with stage IV breast cancer who don’t have any symptoms yet.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Clearwater, Florida and 1 other locations · NCT05115474

• Understanding how tumor shrinkage predicts cancer response in early breast cancer patients

  This study tests if measuring how much breast tumors shrink during chemotherapy can help predict how well the treatment will work for women with early-stage breast cancer.

  Recruiting at 2 sites Phase 2 Baylor Breast Care Center · Houston, Texas and 1 other locations · NCT05020860

Related topics

Quick answers

How many Hormone-receptor-positive Breast Cancer clinical trials are recruiting right now?

29, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 16 countries. The most sites are in United States (19 trials), China (8 trials), Australia (2 trials), United Kingdom (2 trials), Italy (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 12, Phase 1: 5, Phase 1/2: 4, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →